Nabil Saba, MD
Emory University · Department of Hematology and Medical Oncology, Emory University · Emory University Winship Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nabil Saba, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:54 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05814666 · Activity and Safety of Danvatirsen and Pembrolizumab in HNSCCFlamingo Therapeutics NV · terminated · HNSCC · study chair
- Ph3NCT04550260 · Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCAstraZeneca · active not recruiting · Esophageal Squamous Cell Carcinoma · principal investigator
- Ph2NCT00636298 · Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First TherapyEmory University · withdrawn · Esophageal Carcinoma · principal investigator
- Ph2NCT00400205 · Study of Induction Docetaxel, Cisplatin and 5-FluorouracilEmory University · terminated · Squamous Cell Carcinoma, Oral Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.